Search Results: Treatment + Breast Cancer + ER?PR Positive + Stage 4 (9 results)
Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T
https://www.facingourrisk.org/research-clinical-trials/study/364/treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t
Treatment
Phase 1 treatment study for people with advanced solid tumors
CAR-T therapy is a type of immunotherapy that uses the patient's own immune cells in order to treat their cancer. With CAR-T therapy, the immune cells are removed from the blood and enhanced in the lab to improve their ability to kill cancer cells. The goal of this clinical trial is to learn the safety and effectiveness of an experimental CAR-T combination known as CLBR001+ABBV-461 for treating people with metastatic breast cancer. Another goal is to learn the best dose of this combination for treating metastatic breast cancer.
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363/testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349/studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345/treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
This clinical trial is studying a new combination of drugs to treat metastatic, HER2-negative or HER2-low breast cancer in people with an inherited mutation in BRCA1, BRCA2 or PALB2 or a tumor mutation in BRCA1 or BRCA2. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer + ER?PR Positive + Stage 4
54 results
Breast Re-irradiation After Second Ipsilateral Lumpectomy
NCT ID: NCT06867484 (https://clinicaltrials.gov/study/NCT06867484)
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT ID: NCT06388122 (https://clinicaltrials.gov/study/NCT06388122)
Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT ID: NCT03789097 (https://clinicaltrials.gov/study/NCT03789097)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT ID: NCT06841354 (https://clinicaltrials.gov/study/NCT06841354)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT ID: NCT07318805 (https://clinicaltrials.gov/study/NCT07318805)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://clinicaltrials.gov/study/NCT06103864)
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT06878248 (https://clinicaltrials.gov/study/NCT06878248)
National Cancer Institute "Cancer Moonshot Biobank"
NCT ID: NCT04314401 (https://clinicaltrials.gov/study/NCT04314401)
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT ID: NCT06247995 (https://clinicaltrials.gov/study/NCT06247995)
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT ID: NCT06172127 (https://clinicaltrials.gov/study/NCT06172127)
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
NCT ID: NCT05989828 (https://clinicaltrials.gov/study/NCT05989828)
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT ID: NCT06678269 (https://clinicaltrials.gov/study/NCT06678269)
Biomarkers to Detect Endocrine Therapy Resistance
NCT ID: NCT06067503 (https://clinicaltrials.gov/study/NCT06067503)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://clinicaltrials.gov/study/NCT05894239)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
NCT ID: NCT06224673 (https://clinicaltrials.gov/study/NCT06224673)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT ID: NCT06471673 (https://clinicaltrials.gov/study/NCT06471673)
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://clinicaltrials.gov/study/NCT05534438)
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT07112053 (https://clinicaltrials.gov/study/NCT07112053)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
Prospective Breast Cancer Biospecimen Collection
NCT ID: NCT04074720 (https://clinicaltrials.gov/study/NCT04074720)
CDK and Body Composition Study
NCT ID: NCT03697577 (https://clinicaltrials.gov/study/NCT03697577)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT ID: NCT07020117 (https://clinicaltrials.gov/study/NCT07020117)
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
NCT ID: NCT06055881 (https://clinicaltrials.gov/study/NCT06055881)
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://clinicaltrials.gov/study/NCT04563507)
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://clinicaltrials.gov/study/NCT04990921)
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT05081609 (https://clinicaltrials.gov/study/NCT05081609)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT07085767 (https://clinicaltrials.gov/study/NCT07085767)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT ID: NCT06926868 (https://clinicaltrials.gov/study/NCT06926868)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://clinicaltrials.gov/study/NCT03671044)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://clinicaltrials.gov/study/NCT05673200)
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
NCT ID: NCT03987555 (https://clinicaltrials.gov/study/NCT03987555)
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT ID: NCT06590857 (https://clinicaltrials.gov/study/NCT06590857)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://clinicaltrials.gov/study/NCT04683679)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
NCT ID: NCT06260033 (https://clinicaltrials.gov/study/NCT06260033)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://clinicaltrials.gov/study/NCT04923542)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT ID: NCT04567420 (https://clinicaltrials.gov/study/NCT04567420)
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
NCT ID: NCT06525766 (https://clinicaltrials.gov/study/NCT06525766)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT ID: NCT05183828 (https://clinicaltrials.gov/study/NCT05183828)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.